Agata Mostkowska

Agata Mostkowska

Auto-generated profile, based on publicly available information

Agata Mostkowska

Department of Pharmacology and Physiology, Faculty of Medicine University of Montreal Montreal Quebec Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in The FASEB Journal
Verified
Journal Article
Open access
AMAgata Mostkowska
Agata Mostkowska
Guy RousseauGuy Rousseau
Guy Rousseau
NRNoël J. Raynal
Noël J. Raynal
Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off‐label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 115 autoimmune diseases across 17 medical specialties, sourced from over 1530 publications. Our work highlights the extent of its off‐label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune‐related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting cluster of differentiate 20 positive (CD20) B cells in 115 autoimmune diseases.